

Aventus Capital Advises Biocon Limited on Its 10% Stake Sale (USD 274 mn) in Syngene International Limited

February 2023 • Mumbai

	DEAL VALUE	USD 274 mn
	SERVICE	Equity Capital Markets
	SECTOR	Healthcare

Biocon Limited (Biocon) sold its 10% stake in Syngene International Limited (Syngene) on 1st February, 2023, at a price of INR 560 per share, a discount of 0.4% on the previous day's closing price, valued at INR 2,240 crore (USD 274 million). The book was well distributed with 98% long only participation (FI/ DI: 65%/ 35%) from top global investors across classes including sovereign funds, long only FIIs, long only DIIs, pension funds and endowment funds.

| Aventus Capital was the sole advisor and Aventus Spark Institutional Equities was the sole broker to this transaction.

Gaurav Sood, Managing Director & Head, Equity Capital Markets, Aventus Capital said, "We are delighted to partner with Biocon on its stake sale in Syngene for the second time. Quality businesses with experienced management and strong fundamentals continue to witness interest from marquee global and domestic investors including top sovereign and pension funds."

Chintan Kothari, Managing Director & Head, Healthcare Investment Banking, Aventus Capital said, "Innovator focused scaled Indian CDMO1 businesses have a very attractive long term run away. This transaction is a further validation of Syngene's premier position, successful track record of high-quality delivery and execution and strong growth prospects."

Incorporated in 1993, as a subsidiary of Biocon Limited, Syngene International is a contract research and manufacturing company providing drug discovery and development services in India, the U.S. and other countries. The Company serves pharmaceutical, biotechnology, nutrition, animal health and specialty chemical companies.

Biocon is India's largest biopharmaceutical company, delivering high quality Biosimilar, Generic Formulation and API products, as well as research services, to patients and customers around the globe. The Company's

portfolio comprises of products in therapeutic areas such as oncology, immunology and diabetes, among others, serving patients and customers in approximately 120 countries.

¹CDMO - Contract Development and Manufacturing Organization

| About Avendus

Avendus Group is a leading financial services firm with a presence in the areas of Investment Banking, Institutional Equities, Wealth Management, Credit Solutions and Asset Management. Established in 1999 in Mumbai, India, Avendus is today present in 10 cities across India, US and Singapore. Avendus partners with the Indian entrepreneur ecosystem to provide differentiated solutions that enable clients to meet their strategic aspirations.

Avendus Capital, the investment banking arm, is consistently ranked among the top investment banks in the country on the back of its in-depth domain understanding and a best in the class track record of domestic and cross-border transactions. Avendus' wide range of clients is testimony to its ability to serve its corporates throughout their life cycle – from growth stage funding to large-sized transactions, M&A advisory and access to public markets.

Avendus Capital Inc., New York and **Avendus Pte Ltd.**, Singapore are both Avendus Group entities offering services to clients in the US and Southeast Asia respectively.

For more information, please visit www.avendus.com

Deal Release	Avendus Capital Private Limited
Contact: Lynette D'souza Tel: +91 9920847823 Email: lynette.dsouza@avendus.com	Regd. Office: 901, Platina, 9th Floor, Plot No. C-59, Bandra Kurla Complex, Bandra (E), Mumbai 400051